Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaksOACSCDCSTPCD
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks
Sapacitabine is an orally bioavailable prodrug of the nucleoside analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC).Both the prodrug and active metabolite are in clinical trials for hematologic malignancies and/or solid tumors.CNDAC has a unique mechanism of action:after incorporation into DNA,it induces single-strand breaks (SSBs) that are converted into double-strand breaks (DSBs) when cells go through a second S phase.In our previous…查看全部>>
Xiao-Jun Liu;Billie Nowak;Ya-Qing Wang;William Plunkett
Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USADepartment of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USADepartment of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USADepartment of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA
Sapacitabine CNDAC cytarabine gemcitabine homologous recombination
Sapacitabine CNDAC cytarabine gemcitabine homologous recombination
《癌症（英文版）》 2012 (8)
373-380,8
This study was supported by grants from the National Cancer Institute,Department of Health and Human Services,USA (CA28596,CA81534 and CA100632).
评论